Information Provided By:
Fly News Breaks for September 16, 2019
ZYNE
Sep 16, 2019 | 09:47 EDT
Jefferies analyst Andrew Tsai assumed coverage of Zynerba Pharmaceuticals with a Hold rating and $11 price target. At around $12, the shares look fairly valued, Tsai tells investors in a research note. The analyst awaits a better entry point.
News For ZYNE From the Last 2 Days
There are no results for your query ZYNE